| 1. |
- Lawrenson, Kate, et al.
(författare)
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
- 2016
-
Ingår i: Nature Communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 7
-
Tidskriftsartikel (refereegranskat)abstract
- A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10-20), ER-negative BC (P=1.1 × 10-13), BRCA1-associated BC (P=7.7 × 10-16) and triple negative BC (P-diff=2 × 10-5). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10-3) and ABHD8 (P<2 × 10-3). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3′-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk.
|
|
| 2. |
- Hannele, Holttinen, et al.
(författare)
-
Impacts of large amounts of wind power on design and operation of power systems, results of IEA collaboration
- 2009
-
Ingår i: 8th International Workshop on LargeScale Integration of Wind Power into Power Systems as well as on Transmission Networks of Offshore Wind Farms.
-
Konferensbidrag (refereegranskat)abstract
- IEA WIND R&D Task 25 on “Design and Operation of Power Systems with Large Amounts of Wind Power” collects and shares information on wind power impacts on power systems, with analyses and guidelines on methodologies. There are dozens of studies made and ongoing related to wind integration, however, the results are not easy to compare. In the stateoftheart report (October, 2007), and the final report of the 3 years period (July, 2009) the most relevant wind power grid integration studies have been analysed especially regarding methodologies and input data. Several issues that impact on the amount of wind power that can be integrated have been identified. Large balancing areas and aggregation benefits of large areas help in reducing the variability and forecast errors of wind power as well as help in pooling more cost effective balancing resources. System operation and functioning electricity markets at less than dayahead time scales help reduce forecast errors of wind power. Transmission is the key to aggregation benefits, electricity markets and larger balancing areas. Best practices in wind integration studies are described. There is also benefit when adding wind power to power systems: it reduces the total operating costs and emissions as wind replaces fossil fuels and this should be highlighted more in future studies.
|
|
| 3. |
- Holttinen, Hannele, et al.
(författare)
-
Impacts of large amounts of wind power on design and operation of power systems, results of IEA collaboration
- 2011
-
Ingår i: Wind Energy. - : Wiley. - 1095-4244 .- 1099-1824. ; 14:2, s. 179-192
-
Tidskriftsartikel (refereegranskat)abstract
- There are dozens of studies made and ongoing related to wind integration. However, the results are not easy to compare. IEA WIND R&D Task 25 on 'Design and Operation of Power Systems with Large Amounts of Wind Power' collects and shares information on wind generation impacts on power systems, with analyses and guidelines on methodologies. In the state-of-the-art report (October, 2007), and the final report of the 3 years period (July, 2009) the most relevant wind power grid integration studies have been analysed especially regarding methodologies and input data. Several issues that impact on the amount of wind power that can be integrated have been identified. Large balancing areas and aggregation benefits of wide areas help in reducing the variability and forecast errors of wind power as well as help in pooling more cost effective balancing resources. System operation and functioning electricity markets at less than day-ahead time scales help reduce forecast errors of wind power. Transmission is the key to aggregation benefits, electricity markets and larger balancing areas. Best practices in wind integration studies are described. There is also benefit when adding wind power to power systems: it reduces the total operating costs and emissions as wind replaces fossil fuels and this should be highlighted more in future studies.
|
|
| 4. |
- Kawakatsu, Taiji, et al.
(författare)
-
Epigenomic Diversity in a Global Collection of Arabidopsis thaliana Accessions
- 2016
-
Ingår i: Cell. - : Elsevier. - 0092-8674 .- 1097-4172. ; 166:2, s. 492-505
-
Tidskriftsartikel (refereegranskat)abstract
- The epigenome orchestrates genome accessibility, functionality, and three-dimensional structure. Because epigenetic variation can impact transcription and thus phenotypes, it may contribute to adaptation. Here, we report 1,107 high-quality single-base resolution methylomes and 1,203 transcriptomes from the 1001 Genomes collection of Arabidopsis thaliana. Although the genetic basis of methylation variation is highly complex, geographic origin is a major predictor of genome-wide DNA methylation levels and of altered gene expression caused by epialleles. Comparison to cistrome and epicistrome datasets identifies associations between transcription factor binding sites, methylation, nucleotide variation, and co-expression modules. Physical maps for nine of the most diverse genomes reveal how transposons and other structural variants shape the epigenome, with dramatic effects on immunity genes. The 1001 Epigenomes Project provides a comprehensive resource for understanding how variation in DNA methylation contributes to molecular and non-molecular phenotypes in natural populations of the most studied model plant.
|
|
| 5. |
- Monk, Bradley J., et al.
(författare)
-
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
- 2022
-
Ingår i: Journal of Clinical Oncology. - : Lippincott, Williams & Wilkins. - 0732-183X .- 1527-7755. ; 40:34, s. 3952-3964
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSEATHENA (ClinicalTrials.gov identifier: ) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo.METHODSPatients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete resection permitted) and responding to first-line platinum-doublet chemotherapy were randomly assigned 4:1 to oral rucaparib 600 mg twice a day or placebo. Stratification factors were HRD test status, residual disease after chemotherapy, and timing of surgery. The primary end point of investigator-assessed progression-free survival was assessed in a step-down procedure, first in the HRD population (BRCA-mutant or BRCA wild-type/loss of heterozygosity high tumor), and then in the intent-to-treat population.RESULTSAs of March 23, 2022 (data cutoff), 427 and 111 patients were randomly assigned to rucaparib or placebo, respectively (HRD population: 185 v 49). Median progression-free survival (95% CI) was 28.7 months (23.0 to not reached) with rucaparib versus 11.3 months (9.1 to 22.1) with placebo in the HRD population (log-rank P = .0004; hazard ratio [HR], 0.47; 95% CI, 0.31 to 0.72); 20.2 months (15.2 to 24.7) versus 9.2 months (8.3 to 12.2) in the intent-to-treat population (log-rank P < .0001; HR, 0.52; 95% CI, 0.40 to 0.68); and 12.1 months (11.1 to 17.7) versus 9.1 months (4.0 to 12.2) in the HRD-negative population (HR, 0.65; 95% CI, 0.45 to 0.95). The most common grade & GE; 3 treatment-emergent adverse events were anemia (rucaparib, 28.7% v placebo, 0%) and neutropenia (14.6% v 0.9%).CONCLUSIONRucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.
|
|
| 6. |
|
|
